CARA
- Cara Therapeutics, Inc.
()
Overview
Company Summary
Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs to alleviate pain and pruritus (itching) associated with various medical conditions. Their primary focus is on targeting and modulating peripheral receptors in the nervous system, known as peripheral kappa opioid receptors (KORs), for pain management.
Cara Therapeutics utilizes its proprietary technology platform, which combines its expertise in pharmaceutical sciences and KOR biology, to develop novel drug candidates. They aim to address the limitations and potential side effects commonly associated with traditional opioid-based therapies.
The company's lead product candidate is KORSUVA� (difelikefalin), which is being developed as an intravenous (IV) and oral therapy for the treatment of moderate-to-severe pruritus in patients with chronic kidney disease undergoing hemodialysis. Pruritus is a common and distressing symptom experienced by patients with kidney disease, and there are limited treatment options available currently.
Cara Therapeutics is also exploring the potential of KORSUVA� as a treatment for pruritus associated with other conditions, such as atopic dermatitis, psoriasis, and primary biliary cholangitis. Additionally, they have ongoing clinical development programs investigating novel molecules targeting KORs for the management of acute and chronic pain.
Through their research and development efforts, Cara Therapeutics seeks to improve the quality of life for patients suffering from debilitating pain and pruritus while minimizing the risks and adverse effects typically associated with conventional opioid therapies.